All filters
E-Posters
Similar Levels Of HIV-Dna And Residual Viremia Are Found In Virologically Suppressed Individuals Who Continue A Two-Drug Regimen With Dolutegravir Plus One Reverse Transcriptase Inhibitor Or Switch To Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafen
M. M. Santoro
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Case Report: Poor Adherence To Dolutegravir Is Associated With Selection Of Resistance Mutations T66I, G118R, E138A And L74I
M. Pauskar
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Multicentric Castleman Disease HHV-8 Related In A HIV Patient
A. Gjataj
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
HIV Seronegativity After Rapid Art: A Case Demonstrating Future Challenges In HIV Confirmation Testing In The Era Of iART
K. Yan
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Variability In HIV Proviral DNA Genotyping Results From A Single Blood Draw
R. Acosta
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Virological Efficacy And Resistance Evaluation In People Living With HIV Starting An STR Regimen
G. Stella
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Resistant Minority Variants Observed In Failing Patients At Week 48 In Anrs 170 Quatuor Trial (A 4/7 Days Maintenance Strategy Vs A 7/7 Days Regimen In Patients With Controlled Viral Load)
S. Lambert
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Molecular Characterization In Hcv Late Relapser Patients Treated With Direct-Acting Antiviral (DAA) Drugs
M. Rueca
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Clinical And Virological Characteristics And Retreatment Of Patients With Chronic Hepatitis C Virus Infection And Failure To Sofosbuvir, Velapatasvir, And Voxilaprevir In Real-World
F. García
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Pharmaco-Virological Algorithm To Target Risk Of Resistance Among A Population Of HIV-Infected Female Sex Workers In Togo
C. Charpentier
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Impact Of Sexually Transmitted Infections On Seminal HIV Levels Among Undetectable Patients
R. Scutari
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
The Burden Of Serious Non-AIDS-Defining Events Among Admitted cART-Naive HIV/AIDS Patients In China: An Observational Cohort Study
Y. Wang
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Bone Mineral Density In Patients With HIV Infection And Chronic Hepatitis C
A. Timchev
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
The Prevalence Of Hepatitis B Virus Seromarkers In Patients With HIV/Hcv Coinfection. An Egyptian Cross-Sectional Study
I. Naguib
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Seroprevalence And Co-Infections HIV, HBV And HCV Among Clinic Attenders At Laquintinie Hospital In Douala, Cameroon
P. D. Djouela Djoulako
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Using Next-Generation Sequencing To Understand The Phylogenetics And Networks Of Generalised HIV Epidemics In Africa
S. Kemp
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
The Efficacy Of First-Line Therapy Based On Rpv In HIV-Infected Patients With Pre-Existing E138A Mutation In Reverse Transcriptase
A. Kuznetsova
Presented at:
European Meeting on HIV & Hepatitis 2020
E-Posters
Number, Type And Cost Of Microbiological Assays During HIV Pre-Exposure Prophylaxis: The Experience Of A French Hospital
M. Morgat
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Long-Acting Cabotegravir + Rilpivirine for HIV Treatment: FLAIR Week 96 Results
R. D'Amico
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Optimisation of First-Line Antiretroviral Therapy (ART) for Children Living with HIV in Uganda: Translation from policy to action
E. Magongo
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Dual therapy including dolutegravir plus boosted-darunavir ensures high rate of virological control and rare resistance selection at failure in heavily treatment experienced PLWH
D. Armenia
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Dual therapy with Dolutegravir plus Lamivudine in virologically suppressed patients
C. Valente
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Real-world effectiveness of elbasvir/grazoprevir in the treatment of patients with hepatitis C virus genotype 1a infection in Norway
R. Leiva
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV A1 or B Do Not Differentially Impact Cabotegravir In Vitro Potency or Durability
J. Jeffrey
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020